Cardiovascular Complications of COVID-19

Acute and Long-Term Impacts
1. Auflage 2022
ISBN: 978-3-031-15477-5
Verlag: Springer International Publishing

Buch, Englisch, 437 Seiten, Format (B × H): 160 mm x 241 mm, Gewicht: 929 g

Reihe: Contemporary Cardiology

This book is the first comprehensive approach on COVID-19 cardiac complications, both during the acute phase as well as in the long-COVID period. It provides an up-to-date and highly illustrated summary of the biology of SARS-CoV-2, the course of COVID-19, risk factors that worsen the disease in COVID-19 patients, clinical features of COVID-19 patients, COVID-19 cardiological complications, treatment, and prevention methods, and long-term cardiological aspects of COVID-19.
Chapters provide the reader with a contemporary perspective on the emerging links between COVID-19 and cardiovascular disease. In addition, this volume discusses the clinical implications and therapeutic goals in patients with COVID-19 and cardiac complications, as well as possible therapeutic options. It also offers clear recommendations on how to manage (both non- and pharmacologically) to avoid the increased number of COVID-19 related deaths due to CVD and its risk factors.

Cardiovascular Complications of COVID-19 will be the primary resource for physicians, residents, fellows, and nursed and medical students in the fields of cardiology and COVID-19/infectious diseases as well as healthcare providers that initiate preventive activities and dedicated programs.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Banach, Maciej

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Kardiologie, Angiologie, Phlebologie

Inhaltsverzeichnis

I. Introduction

1.       Biology of SARS-CoV-2 coronavirus - origin, structure, and variants

2.       COVID-19 epidemiology and differences in incidence and mortality between countries

3.       Clinical symptoms and course of COVID-19

4.       Risk factors of developing COVID-19 and its severe course

5.       Prognosis in COVID-19 patients - statistics, risk factors

II. Cardiovascular complications of the acute phase of COVID-19

6.       Myocardial injury in COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment)

7.       Acute coronary syndrome - destabilization of atherosclerotic plaque in COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment)

8.       Acute vascular injury (epidemiology, influence on prognosis, pathogenesis, treatment)

9.       Myocarditis in COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment)

10.    Heart failure in COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment)

11.    Acute circulatory failure in COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment)

12.    Cardiomyopathy in COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment)

13.    Arrythmias in COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment)

14.    Thromboembolic events in COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment)

15.    Stroke in COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment)

16.    Pulmonary embolism after COVID-19 (epidemiology, influence on prognosis, pathogenesis, treatment)

17.    Cardiac complications of drugs used in COVID-19 therapy

III. Influence of the treatment of cardiovascular diseases on the course of COVID-19

18.    Omega-3 acids and COVID-19 (mechanism of action, effect on prognosis)

19.    Statins and COVID-19 (mechanism of action, effect on prognosis)

20.    ACEI / ARB in COVID-19 (mechanism of action, effect on prognosis)

21.    Colchicine in COVID-19 (mechanism of action, effect on prognosis)

22.    Antiplatelets drugs (mechanism of action, effect on prognosis)

23.    Other medications (mechanism of action, effect on prognosis)

IV. Cardiovascular complications of long-COVID-19

24.    Long COVID-19 - definition, epidemiology, and clinical implications

25.    Cardiovascular complications of Long-COVID – prevalence, diagnosis, risk factors.

26.  Cardiovascular complications of Long-COVID – management.

V. The impact of the Covid-19 pandemic on the CVD diagnosis, monitoring and outcomes.

VI. The impact of the COVID-19 pandemic on e-services and digital tools development in medicine.

Über Autor(innen)

Prof. Maciej Banach was an Undersecretary of State at the Ministry of Science and Higher Education of the Republic of Poland (2010-2012), and a President of the Polish Mother's Memorial Hospital - Research Institute (PMMHRI) (2014-2021). He is a Head of Cardiovascular Research Centre at University of Zielona Gora, full Professor of Cardiology at the Medical University of Lodz (MUL) and PMMHRI, Head of Department of Preventive Cardiology and Lipidology at the Medical University of Lodz (MUL), Poland. 

He is a Secretary of the European Atherosclerosis Society (EAS) (2021-2024) and member of the Scientific and Health Policy Advisory Group of the FH Europe. He is a Founder and Head of the Polish Lipid Association (PoLA) (2011-) and Lodz Chapter of Polish Society of Hypertension (2009-). He is the founder of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (2012-) – a group of over 150 worldwide experts aimed to investigate the most important issues in the field of lipid disorders, hypertension, nutrition and cardiovascular risk, as well as the President of the International Lipid Expert Panel (ILEP; ilep.eu) (2015-), currently with >100 recognized worldwide experts, which has been founded to prepare recommendations in the area of preventive cardiology, atherosclerosis and natural products in the most debatable issues that have not been covered in the existing guidelines. He is also a member of the REPROGRAM and CAPISCO Consortia – a group of experts challenging with Covid-19 pandemic, member of 2 largest worldwide databases – the Global Burden of Disease (GDB) (IHME, University of Washington, Seattle, US) and Non-Communicable Diseases Risk Factor Collaboration (NCD-RisC, Imperial College of London, UK). He is also Founder and President of the foundation – Think-Tank “Innovation for Health”, which gathers six main health research institutes and over 40 medical business representatives in Poland with main aim to make innovations in the medical area in Poland. He is a Visiting Professor of University of Alabama at Birmingham (UAB), University of Medicine and Pharmacy Victor Babes in Timisoara, Romania (2014-), and University of California, Irvine (UCI), CA, USA (2021-).  Prof. Banach has published over 1200 original articles, reviews, editorials, and book chapters in the field of hypertension, dyslipidemia, cardiology, and risk stratification. His combined IF (for only full-text manuscripts) is over 10,000 pts, number of citations: 45,364 (acc. Web of Science Core Collection/Publons), 51,348 (acc. SCOPUS), 61,108 (acc. ResearchGate), and 74,361 (acc. Google Scholar) with Hirsch’s Index = 80 (WoS/Publons), 81 (SCOPUS), 95 (ResearchGate) and 101 (i10-index: 634) (Google Scholar) – being within 1% the highest cited scientists in the world (in the research area of Clinical Medicine and Pharmacology and Toxicology) according to Essential Science Indicators by Clarivate (with 53 TOP Papers). Prof. Banach is also within top 5 worldwide experts according to ExpertScape in the field of statins (3), dyslipidemias (4), lipoproteins (4), HDL cholesterol (5) and LDL lipoproteins (5). He is also a 1% Top Reviewer in the areas of Clinical Medicine and Cross-Field (in 2018 and 2019) by Publons/Clarivate and Publons Academy Mentor.